Epicin 2 mg/ml (IV Infusion)
10 mg vial: ৳ 850.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Epirubicin hydrochloride |
| Company | Techno drugs ltd |
Indications
- Component of adjuvant therapy
- Patients with axillary node tumor involvement
- Resection of primary breast cancer
Pharmacology
- Anthracycline with cytotoxic properties
- Inhibits DNA and RNA synthesis
- Triggers DNA cleavage by topoisomerase II
- Inhibits DNA helicase
- Generates cytotoxic free radicals
- Rapid and wide distribution into tissues
- Binding to plasma proteins
- Extensively and rapidly metabolized by the liver
- Eliminated through biliary and urinary excretion
- Terminal elimination half-life of 30-40 hrs
Dosage and administration
- Administered by intravenous infusion
- Given in repeated 3-to 4-week cycles
- Total dose given on day 1 or divided on days 1 and 8
- Recommended dose of 100 to 120 mg/m²
- Specific regimens CEF-120 and FEC-100
Interaction
- Concomitant use with cardioactive compounds
- Interaction with Cimetidine
- Potential additive toxicity with other cytotoxic drugs
- Effects of Paclitaxel and Docetaxel
- Possible inflammatory recall reaction with radiation therapy
- Liver metabolism affected by concomitant therapies
Contraindications
- Known hypersensitivity to Epirubicin or similar drugs
Side effects
- Myelosuppression
- Cardiotoxicity
- Alopecia
- Hyperpyrexia
- Lethargy
- Amenorrhea
- Nausea
- Vomiting
- Diarrhea
- Fever
- Rash
- Anorexia
- Reddish appearance of urine for 1-2 days
Pregnancy and lactation
- Pregnancy Category D
- Potential excretion in human milk
- Decision-making for nursing mothers
Precautions and warnings
- Storage and handling precautions
- Administered under supervision of qualified physicians
- Baseline assessment prior to treatment
- Monitoring for myelosuppression and cardiotoxicity
- Supportive care for complications
Use in special populations
- Dosage adjustments based on toxicities
- Considerations for bone marrow dysfunction
- Hepatic and renal impairment recommendations
- Unknown safety and effectiveness in pediatric patients
- Monitoring toxicity in elderly female patients
Overdose effects
- Supportive treatment in case of overdose
- Observation for delayed CHF
Therapeutic class
- Cytotoxic chemotherapy
Storage conditions
- Refrigeration at 2-8°C
- Protection from light
- Keep out of reach of children